Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists

被引：20

作者：

Zhang, Jinfeng ^{[1
,2
]}

Yan, Wenzhong ^{[1
]}

Duan, Wenwen ^{[1
]}

Wuthrich, Kurt ^{[1
,3
]}

Cheng, Jianjun ^{[1
]}

机构：

[1] ShanghaiTech Univ, IHuman Inst, Shanghai 201210, Peoples R China

[2] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China

[3] Scripps Res, Dept Integrated Struct & Computat Biol, La Jolla, CA 92037 USA

来源：

PHARMACEUTICALS | 2020年 / 13卷 / 09期

关键词：

GPCR; immuno-oncology; Parkinson's disease; drug binding modes; cancer therapy; PARKINSONS-DISEASE; CRYSTAL-STRUCTURE; DERIVATIVES; ZM241385; POTENT; ZM-241385; BLOCKADE; BINDING; CELLS;

D O I：

10.3390/ph13090237

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The A(2A) adenosine receptor (A(2A) AR) plays critical roles in human physiology and pathophysiology, which makes it an important drug target. Previous drug-discovery efforts targeting the A(2A) AR have been focused on the use of A(2A) AR antagonists for the treatment of Parkinson's disease. More recently, the A(2A) AR has attracted additional attention for its roles in immuno-oncology, and a number of A(2A) AR antagonists are currently used as lead compounds for antitumor drugs in both preclinical models and clinical trials. This review surveys recent advances in the development of A(2A) AR antagonists for cancer immunotherapy. The therapeutic potential of representative A(2A) AR antagonists is discussed based on both animal efficacy studies and clinical data.

引用

页码：1 / 14

页数：14